Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
Hims & Hers HealthJohnson & Johnson
Last price
$27.68$273.20
Currency
USD
USD
$6.9B$662B
-41.79
-$0.62$6.58
2.420.21
0$5.28
01.95%
Sector
HealthHealth
Employees
2,442138,200
Ticker
$HIMS$JNJ
Primary listing
NYSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $HIMS or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.